Axsome Therapeutics, Inc. (AXSM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Axsome Therapeutics, Inc. (AXSM) trades at $234.48 with AI Score 68/100 (Grade B+). Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. Market cap: 13B, Sector: Healthcare.
Last analyzed: May 10, 2026AXSM stock analysis for 2026: Analysts have set a consensus price target of $223.66 for Axsome Therapeutics, Inc., suggesting 4.6% downside from the current price of $234.48. The AI MoonshotScore is 68/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
AXSM: 4/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
Axsome Therapeutics, Inc. (AXSM) Healthcare & Pipeline Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company specializing in novel therapies for central nervous system disorders, including depression, Alzheimer's agitation, migraine, narcolepsy and fibromyalgia. With a focus on innovative treatments, Axsome aims to address unmet needs in the CNS market, positioning itself as a key player in the biotechnology sector.
What Is the Investment Thesis for AXSM?
Axsome Therapeutics presents a compelling investment thesis driven by its diverse pipeline of CNS therapies and strategic focus on addressing unmet medical needs. With a market capitalization of $9.67 billion, Axsome has established a strong presence in the biotechnology sector. Key value drivers include the successful development and commercialization of AXS-05 for MDD and Alzheimer's disease agitation, as well as AXS-07 for migraine and AXS-12 for narcolepsy. The company's high gross margin of 92.6% indicates strong pricing power and efficient operations. Upcoming catalysts include Phase III clinical trial results for AXS-05 in Alzheimer's disease agitation and continued progress in the development of AXS-12 and AXS-14. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's negative profit margin of -26.6% reflects ongoing investment in research and development, which is expected to yield long-term returns.
Based on FMP financials and quantitative analysis
AXSM Key Highlights
- Market Cap of $9.67B reflects investor confidence in Axsome's pipeline and growth potential.
- Gross Margin of 92.6% indicates strong pricing power and efficient manufacturing processes.
- Beta of 0.47 suggests lower volatility compared to the broader market, making it a relatively stable investment.
- Focus on CNS disorders addresses a significant and growing market with unmet medical needs.
- Extensive pipeline including AXS-05, AXS-07, AXS-12 and AXS-14 provides multiple opportunities for revenue generation.
Who Are AXSM's Competitors?
Who Are AXSM's Competitors?
AXSM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | $238.57 | -0.62% | 15B | 58 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $73.09 | -2.75% | 11B | 72 |
| ABVX Abivax S.A. | $124.65 | -1.49% | 9B | 76 |
| NUVL Nuvalent, Inc. | $110.39 | +1.02% | 9B | 48 |
| CYTK Cytokinetics, Incorporated | $73.68 | -0.96% | $9.17B | 65 |
| ANAB AnaptysBio, Inc. | $57.69 | +1.54% | $2.49B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $17.34 | -3.77% | 2B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $3.82 | -0.26% | 361M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AXSM's Key Strengths?
- Innovative pipeline of CNS therapies.
- Strong intellectual property protection.
- Experienced management team.
- High gross margin.
What Are AXSM's Weaknesses?
- Negative profit margin.
- Reliance on successful clinical trial outcomes.
- Limited commercialization experience.
- High R&D spending.
What Could Drive AXSM Stock Higher?
- Phase III clinical trial results for AXS-05 in Alzheimer's disease agitation (2027-2028).
- Potential FDA approval and commercial launch of AXS-07 for migraine (2026-2027).
- Phase III clinical trial results for AXS-12 in narcolepsy (2027-2028).
- Phase III clinical trial results for AXS-14 in fibromyalgia (2028-2029).
- Continued progress in research and development of novel CNS therapies.
What Are the Key Risks for AXSM?
- Clinical trial failures could delay or halt the development of key pipeline products.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from established pharmaceutical companies with greater resources.
- Patent expiration and loss of exclusivity for key products.
- Dependence on successful commercialization of approved products.
What Are the Growth Opportunities for AXSM?
- Expansion of AXS-05 into Alzheimer's Disease Agitation: AXS-05 is currently in Phase III clinical trials for the treatment of agitation associated with Alzheimer's disease. Successful completion of these trials and subsequent regulatory approval could open up a significant market opportunity, as agitation affects a large proportion of Alzheimer's patients. The Alzheimer's disease therapeutics market is projected to reach $12.6 billion by 2028, providing a substantial revenue opportunity for Axsome. Timeline: 2027-2028.
- Development and Commercialization of AXS-07 for Migraine: AXS-07 is a novel, oral, rapidly absorbed medicine for the acute treatment of migraine. With two successful Phase III trials completed, AXS-07 has the potential to capture a significant share of the migraine therapeutics market, which is estimated to reach $3.5 billion by 2027. Axsome's focus on developing a rapidly acting and effective migraine treatment positions it well to compete in this market. Timeline: 2026-2027.
- Advancement of AXS-12 for Narcolepsy: AXS-12, a selective norepinephrine reuptake inhibitor, is in Phase III clinical trials for the treatment of narcolepsy. The narcolepsy therapeutics market is expected to grow to $2.5 billion by 2028, driven by increasing awareness and diagnosis of the condition. Axsome's focus on developing a targeted therapy for narcolepsy positions it to capitalize on this growth. Timeline: 2027-2028.
- Progress of AXS-14 for Fibromyalgia: AXS-14 is a novel, oral, and investigational medicine in Phase III trials for the treatment of fibromyalgia. The fibromyalgia treatment market is projected to reach $3.9 billion by 2029. Successful development and commercialization of AXS-14 could provide Axsome with a significant revenue stream and expand its presence in the pain management market. Timeline: 2028-2029.
- Strategic Partnerships and Collaborations: Axsome's research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation demonstrates its commitment to strategic partnerships. Expanding these collaborations could provide access to new technologies, therapeutic targets, and markets. Strategic partnerships can accelerate drug development, reduce costs, and enhance Axsome's competitive position in the biotechnology industry. Ongoing.
What Opportunities Does AXSM Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Acquisition of complementary technologies.
- Increasing prevalence of CNS disorders.
What Threats Does AXSM Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent expiration.
What Are AXSM's Competitive Advantages?
- Patented drug formulations provide exclusivity and protection from competition.
- Strong clinical data supports the efficacy and safety of its products.
- Focus on novel mechanisms of action differentiates its products from existing treatments.
- Strategic partnerships enhance its research and development capabilities.
What Does AXSM Do?
Axsome Therapeutics, Inc., founded in 2012 and headquartered in New York City, is a biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. The company's mission is to address significant unmet medical needs in CNS diseases through novel, differentiated treatments. Axsome's product pipeline includes a range of therapeutic candidates targeting major depressive disorder (MDD), Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Key products in development include AXS-05, an oral NMDA receptor antagonist with multimodal activity, being developed for MDD, resistant depression, Alzheimer's disease agitation, and smoking cessation. AXS-07 is a novel, oral, rapidly absorbed medicine for the acute treatment of migraine. AXS-12, a selective norepinephrine reuptake inhibitor, is in development for narcolepsy. AXS-14 is being developed for fibromyalgia. Axsome's strategic approach involves identifying promising therapeutic targets, developing differentiated drug candidates, and conducting rigorous clinical trials to demonstrate efficacy and safety. The company also has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation, highlighting its commitment to scientific partnerships and expanding its therapeutic reach. Axsome Therapeutics operates primarily in the United States.
What Products and Services Does AXSM Offer?
- Develops novel therapies for central nervous system (CNS) disorders.
- Focuses on treatments for major depressive disorder (MDD) and resistant depression.
- Develops therapies for Alzheimer's disease agitation.
- Creates treatments for the acute treatment of migraine.
- Develops therapies for narcolepsy.
- Develops therapies for fibromyalgia.
How Does AXSM Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval from the FDA.
- Commercializes approved products through sales and marketing efforts.
What Industry Does AXSM Operate In?
Axsome Therapeutics operates within the biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The CNS therapeutics market is a significant segment within the broader pharmaceutical industry, driven by the increasing prevalence of neurological and psychiatric disorders. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, all vying for market share. Axsome differentiates itself through its focus on novel mechanisms of action and differentiated drug candidates. The biotechnology industry is expected to continue growing, driven by advancements in genomics, proteomics, and personalized medicine.
Who Are AXSM's Key Customers?
- Patients suffering from CNS disorders.
- Healthcare providers who prescribe medications.
- Hospitals and clinics that administer treatments.
- Pharmacies that dispense medications.
AXSM Financials
AXSM Latest News
-
10 Health Care Stocks Whale Activity In Today's Session
benzinga · Jun 5, 2026
-
Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says
MT Newswires · May 27, 2026
-
Axsome Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · May 27, 2026
-
Axsome Therapeutics Presents New AUVELITY Data In Major Depressive Disorder At ASCP 2026 Annual Meeting
benzinga · May 26, 2026
AXSM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AXSM.
Price Targets
Consensus target: $223.66
AXSM MoonshotScore
What does this score mean?
The MoonshotScore rates AXSM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are AXSM's Competitors?
Latest News
10 Health Care Stocks Whale Activity In Today's Session
Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics Presents New AUVELITY Data In Major Depressive Disorder At ASCP 2026 Annual Meeting
Latest Axsome Therapeutics, Inc. Analysis
Leadership: Herriot Tabuteau
CEO
Herriot Tabuteau serves as the Chief Executive Officer of Axsome Therapeutics, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Axsome, he held leadership positions at various healthcare companies, focusing on corporate strategy, business development, and product commercialization. Tabuteau's expertise spans across multiple therapeutic areas, including CNS disorders, oncology, and cardiovascular diseases. He holds advanced degrees in medicine and business administration.
Track Record: Under Herriot Tabuteau's leadership, Axsome Therapeutics has achieved significant milestones in the development and commercialization of its CNS therapies. Key achievements include the advancement of AXS-05 through clinical trials, the acquisition of regulatory approvals, and the establishment of strategic partnerships. Tabuteau has also overseen the expansion of Axsome's product pipeline and the strengthening of its intellectual property portfolio. His strategic decisions have positioned Axsome as a key player in the biotechnology industry.
Axsome Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Axsome Therapeutics, Inc. do?
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. Their primary focus is on addressing unmet medical needs in conditions such as major depressive disorder (MDD), Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. The company develops proprietary drug candidates, conducts clinical trials to demonstrate their safety and efficacy, and seeks regulatory approval from the FDA. Axsome aims to provide innovative treatment options for patients suffering from debilitating CNS conditions, improving their quality of life.
What do analysts say about AXSM stock?
Analyst coverage of Axsome Therapeutics (AXSM) generally reflects optimism regarding the company's pipeline and potential for growth in the CNS therapeutics market. Key valuation metrics include price targets based on projected revenue from AXS-05, AXS-07, AXS-12, and AXS-14. Growth considerations focus on the successful completion of clinical trials, regulatory approvals, and commercial launch of these products. Analyst consensus typically highlights the company's innovative approach to CNS disorders and its potential to capture market share from existing treatments. However, analysts also acknowledge the risks associated with clinical trial outcomes and regulatory uncertainties.
What are the main risks for AXSM?
Axsome Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures pose a significant threat, as the company's pipeline relies on the successful demonstration of efficacy and safety. Regulatory hurdles, including potential delays or rejection of FDA approval, could also impact the company's growth prospects. Competition from established pharmaceutical companies with greater resources and market presence is another ongoing risk. Additionally, patent expiration and loss of exclusivity for key products could erode Axsome's market share and profitability. Dependence on successful commercialization of approved products also presents a risk, as market adoption and sales performance may vary.
What are the key factors to evaluate for AXSM?
Axsome Therapeutics, Inc. (AXSM) currently holds an AI score of 68/100, indicating moderate score. The stock trades at a P/E of 39.8x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $223.66 (-5% from $234.48). Key strength: Innovative pipeline of CNS therapies. Primary risk to monitor: Clinical trial failures could delay or halt the development of key pipeline products. This is not financial advice.
How frequently does AXSM data refresh on this page?
AXSM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AXSM's recent stock price performance?
Recent price movement in Axsome Therapeutics, Inc. (AXSM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $223.66 implies 5% downside from here. Notable catalyst: Innovative pipeline of CNS therapies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AXSM overvalued or undervalued right now?
Determining whether Axsome Therapeutics, Inc. (AXSM) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 39.8. Analysts target $223.66 (-5% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AXSM?
Before investing in Axsome Therapeutics, Inc. (AXSM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of 2026-05-10.